Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.08
MDT's Cash to Debt is ranked higher than
64% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MDT: 1.08 )
MDT' s 10-Year Cash to Debt Range
Min: 0.15   Max: 9.58
Current: 1.08

0.15
9.58
Equity to Asset 0.37
MDT's Equity to Asset is ranked higher than
61% of the 450 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MDT: 0.37 )
MDT' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.82
Current: 0.37

0.37
0.82
Interest Coverage 10.06
MDT's Interest Coverage is ranked higher than
51% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 234.31 vs. MDT: 10.06 )
MDT' s 10-Year Interest Coverage Range
Min: 6.58   Max: 352.69
Current: 10.06

6.58
352.69
F-Score: 5
Z-Score: 1.80
M-Score: -2.86
WACC vs ROIC
2.76%
17.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.17
MDT's Operating margin (%) is ranked higher than
95% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. MDT: 22.17 )
MDT' s 10-Year Operating margin (%) Range
Min: 16.71   Max: 66.79
Current: 22.17

16.71
66.79
Net-margin (%) 17.83
MDT's Net-margin (%) is ranked higher than
94% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. MDT: 17.83 )
MDT' s 10-Year Net-margin (%) Range
Min: 11.03   Max: 22.78
Current: 17.83

11.03
22.78
ROE (%) 15.99
MDT's ROE (%) is ranked higher than
91% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 5.02 vs. MDT: 15.99 )
MDT' s 10-Year ROE (%) Range
Min: 14.54   Max: 32.99
Current: 15.99

14.54
32.99
ROA (%) 7.56
MDT's ROA (%) is ranked higher than
86% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. MDT: 7.56 )
MDT' s 10-Year ROA (%) Range
Min: 8.42   Max: 23.74
Current: 7.56

8.42
23.74
ROC (Joel Greenblatt) (%) 64.35
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. MDT: 64.35 )
MDT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 44.45   Max: 153.66
Current: 64.35

44.45
153.66
Revenue Growth (3Y)(%) 5.40
MDT's Revenue Growth (3Y)(%) is ranked higher than
76% of the 344 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. MDT: 5.40 )
MDT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.2   Max: 17.9
Current: 5.4

4.2
17.9
EBITDA Growth (3Y)(%) 3.50
MDT's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. MDT: 3.50 )
MDT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -15.5   Max: 45.4
Current: 3.5

-15.5
45.4
EPS Growth (3Y)(%) 2.30
MDT's EPS Growth (3Y)(%) is ranked higher than
77% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. MDT: 2.30 )
MDT' s 10-Year EPS Growth (3Y)(%) Range
Min: -4.7   Max: 27.1
Current: 2.3

-4.7
27.1
» MDT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MDT Guru Trades in Q1 2014

Steven Cohen 153,212 sh (+726.25%)
Joel Greenblatt 244,649 sh (+170.38%)
HOTCHKIS & WILEY 2,066,800 sh (+18.73%)
Vanguard Health Care Fund 11,336,900 sh (+7.63%)
Bill Nygren 4,585,000 sh (+4.56%)
Scott Black 43,053 sh (+3.29%)
John Buckingham 18,828 sh (+1.73%)
Diamond Hill Capital 5,349,218 sh (+1.45%)
Bill Frels 4,124,297 sh (+0.82%)
Manning & Napier Advisors, Inc 203,440 sh (+0.41%)
John Keeley 34,160 sh (unchged)
John Hussman 250,000 sh (unchged)
Arnold Van Den Berg Sold Out
Jean-Marie Eveillard Sold Out
PRIMECAP Management 31,570,188 sh (-0.14%)
Jim Simons 1,507,100 sh (-0.35%)
Dodge & Cox 8,982,143 sh (-0.42%)
Jeff Auxier 150,720 sh (-0.66%)
Ken Fisher 6,853 sh (-2.38%)
James Barrow 31,718,209 sh (-2.83%)
Chuck Royce 128,800 sh (-3.3%)
Pioneer Investments 809,321 sh (-7.82%)
Jeremy Grantham 7,050,459 sh (-30.79%)
Ray Dalio 87,345 sh (-34%)
Paul Tudor Jones 11,100 sh (-65.52%)
» More
Q2 2014

MDT Guru Trades in Q2 2014

Robert Olstein 115,000 sh (New)
Jean-Marie Eveillard 2,098,343 sh (New)
Mario Gabelli 40,000 sh (New)
Jim Simons 2,312,700 sh (+53.45%)
Pioneer Investments 1,113,090 sh (+37.53%)
Vanguard Health Care Fund 12,402,000 sh (+9.39%)
James Barrow 32,340,234 sh (+1.96%)
John Buckingham 19,010 sh (+0.97%)
Bill Frels 4,146,152 sh (+0.53%)
Bill Nygren 4,605,000 sh (+0.44%)
Steven Cohen 250,000 sh (unchged)
Steven Cohen 933,000 sh (unchged)
Ray Dalio Sold Out
John Hussman Sold Out
Manning & Napier Advisors, Inc Sold Out
Scott Black 42,983 sh (-0.16%)
Jeff Auxier 149,320 sh (-0.93%)
John Keeley 33,460 sh (-2.05%)
Dodge & Cox 8,776,593 sh (-2.29%)
Paul Tudor Jones 10,500 sh (-5.41%)
PRIMECAP Management 29,602,228 sh (-6.23%)
HOTCHKIS & WILEY 1,932,500 sh (-6.5%)
Ken Fisher 6,015 sh (-12.23%)
Diamond Hill Capital 4,605,630 sh (-13.9%)
Jeremy Grantham 5,518,126 sh (-21.73%)
Chuck Royce 66,100 sh (-48.68%)
Joel Greenblatt 9,398 sh (-96.16%)
» More
Q3 2014

MDT Guru Trades in Q3 2014

Ray Dalio 27,045 sh (New)
Ruane Cunniff 9,700 sh (New)
Andreas Halvorsen 1,841,414 sh (New)
Joel Greenblatt 496,211 sh (+5179.96%)
HOTCHKIS & WILEY 3,230,958 sh (+67.19%)
Robert Olstein 142,000 sh (+23.48%)
Paul Tudor Jones 11,500 sh (+9.52%)
Ken Fisher 6,165 sh (+2.49%)
Bill Nygren 4,690,000 sh (+1.85%)
Dodge & Cox 8,864,623 sh (+1%)
John Buckingham 19,152 sh (+0.75%)
James Barrow 32,479,848 sh (+0.43%)
Mario Gabelli 40,000 sh (unchged)
Vanguard Health Care Fund 12,402,000 sh (unchged)
Pioneer Investments 976,081 sh (unchged)
John Keeley 33,460 sh (unchged)
Scott Black Sold Out
Chuck Royce Sold Out
PRIMECAP Management 29,535,573 sh (-0.23%)
Jeff Auxier 146,345 sh (-1.99%)
Jim Simons 2,200,400 sh (-4.86%)
Bill Frels 3,768,038 sh (-9.12%)
Jean-Marie Eveillard 1,790,484 sh (-14.67%)
Diamond Hill Capital 3,703,791 sh (-19.58%)
Steven Cohen 265,300 sh (-71.56%)
Jeremy Grantham 551,007 sh (-90.01%)
» More
Q4 2014

MDT Guru Trades in Q4 2014

John Hussman 200,000 sh (New)
Steven Cohen 658,900 sh (+148.36%)
Ray Dalio 36,632 sh (+35.45%)
Vanguard Health Care Fund 13,047,000 sh (+5.2%)
James Barrow 32,638,454 sh (+0.49%)
Ken Fisher 6,193 sh (+0.45%)
Bill Nygren 4,690,000 sh (unchged)
Jim Simons Sold Out
Andreas Halvorsen Sold Out
Jeff Auxier 145,895 sh (-0.31%)
John Buckingham 19,051 sh (-0.53%)
Dodge & Cox 8,817,773 sh (-0.53%)
Diamond Hill Capital 3,678,388 sh (-0.69%)
HOTCHKIS & WILEY 3,207,884 sh (-0.71%)
John Keeley 33,180 sh (-0.84%)
Robert Olstein 134,000 sh (-5.63%)
Bill Frels 3,396,496 sh (-9.86%)
Pioneer Investments 788,292 sh (-19.24%)
Jean-Marie Eveillard 1,236,314 sh (-30.95%)
PRIMECAP Management 18,578,166 sh (-37.1%)
Ruane Cunniff 4,700 sh (-51.55%)
Paul Tudor Jones 3,800 sh (-66.96%)
Mario Gabelli 10,000 sh (-75%)
Joel Greenblatt 19,608 sh (-96.05%)
Jeremy Grantham 4,046 sh (-99.27%)
Steven Romick -2,425,900 sh (-9999%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-12-31 New Buy1.4%$61.81 - $75.57 $ 78.1912%200000
PRIMECAP Management 2014-12-31 Reduce -37.1%0.74%$61.81 - $75.57 $ 78.1912%18578166
Andreas Halvorsen 2014-12-31 Sold Out 0.46%$61.81 - $75.57 $ 78.1912%0
Joel Greenblatt 2014-12-31 Reduce -96.05%0.3%$61.81 - $75.57 $ 78.1912%19608
Vanguard Health Care Fund 2014-12-31 Add 5.2%0.11%$61.81 - $75.57 $ 78.1912%13047000
Jean-Marie Eveillard 2014-12-31 Reduce -30.95%0.09%$61.81 - $75.57 $ 78.1912%1236314
Mario Gabelli 2014-12-31 Reduce -75%0.01%$61.81 - $75.57 $ 78.1912%10000
Ray Dalio 2014-12-31 Add 35.45%0.01%$61.81 - $75.57 $ 78.1912%36632
Ruane Cunniff 2014-12-31 Reduce -51.55%$61.81 - $75.57 $ 78.1912%4700
Andreas Halvorsen 2014-09-30 New Buy0.46%$61 - $66.53 $ 78.1923%1841414
Scott Black 2014-09-30 Sold Out 0.4%$61 - $66.53 $ 78.1923%0
Joel Greenblatt 2014-09-30 Add 5179.96%0.3%$61 - $66.53 $ 78.1923%496211
HOTCHKIS & WILEY 2014-09-30 Add 67.19%0.29%$61 - $66.53 $ 78.1923%3230958
Robert Olstein 2014-09-30 Add 23.48%0.21%$61 - $66.53 $ 78.1923%142000
Ray Dalio 2014-09-30 New Buy0.01%$61 - $66.53 $ 78.1923%27045
Ruane Cunniff 2014-09-30 New Buy$61 - $66.53 $ 78.1923%9700
John Hussman 2014-06-30 Sold Out 1.2%$58.05 - $64.67 $ 78.1929%0
Robert Olstein 2014-06-30 New Buy0.99%$58.05 - $64.67 $ 78.1929%115000
Jean-Marie Eveillard 2014-06-30 New Buy0.32%$58.05 - $64.67 $ 78.1929%2098343
Joel Greenblatt 2014-06-30 Reduce -96.16%0.22%$58.05 - $64.67 $ 78.1929%9398
Vanguard Health Care Fund 2014-06-30 Add 9.39%0.18%$58.05 - $64.67 $ 78.1929%12402000
PRIMECAP Management 2014-06-30 Reduce -6.23%0.14%$58.05 - $64.67 $ 78.1929%29602228
Ray Dalio 2014-06-30 Sold Out 0.04%$58.05 - $64.67 $ 78.1929%0
Mario Gabelli 2014-06-30 New Buy0.01%$58.05 - $64.67 $ 78.1929%40000
Arnold Van Den Berg 2014-03-31 Sold Out 0.72%$53.6 - $60.84 $ 78.1934%0
Vanguard Health Care Fund 2014-03-31 Add 7.63%0.14%$53.6 - $60.84 $ 78.1934%11336900
Joel Greenblatt 2014-03-31 Add 170.38%0.14%$53.6 - $60.84 $ 78.1934%244649
Ray Dalio 2014-03-31 Reduce -34%0.02%$53.6 - $60.84 $ 78.1934%87345
Jean-Marie Eveillard 2014-03-31 Sold Out $53.6 - $60.84 $ 78.1934%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Medtronic PLC

Bill Frels Comments on Medtronic Inc - Oct 20, 2014

Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone.

As of September 30, 2014, the market value of the Growth Fund’s holding in Medtronic was $24 per share greater than its cost basis. We estimate that our typical shareholder, that holds the Growth Fund in a taxable amount, will experience about a $6.00 per share tax liability. We do not offer tax advice; each shareholder should consult a tax advisor about his/her particular circumstance. Providing that there are no significant changes, our current thinking leads us to believe that voting for the merger is in our shareholders’ best interest. We will keep you posted as the voting date is finalized or if we learn of any other developments regarding the merger plans.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jul 31, 2014

Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share.

From Bill Frels (Trades, Portfolio)’ Mairs & Power Growth Fund Second Quarter 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jun 25, 2014

Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue.



From Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary.



Check out Bill Frels latest stock trades

Top Ranked Articles about Medtronic PLC

Steven Romick Shorts Alibaba, Medtronic in Q4
Steven Romick (Trades, Portfolio) is the portfolio manager of the long-short FPA Crescent Fund. During the fourth quarter, Romick shorted four additional positions, bringing the fund’s total number of short positions to 29. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue. Read more...
Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary
March 31, 2014 Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.80
MDT's P/E(ttm) is ranked higher than
87% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 120.60 vs. MDT: 24.80 )
MDT' s 10-Year P/E(ttm) Range
Min: 10.14   Max: 43.51
Current: 24.8

10.14
43.51
Forward P/E 18.45
MDT's Forward P/E is ranked higher than
92% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDT: 18.45 )
N/A
PE(NRI) 25.00
MDT's PE(NRI) is ranked higher than
87% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 94.20 vs. MDT: 25.00 )
MDT' s 10-Year PE(NRI) Range
Min: 10.13   Max: 43.51
Current: 25

10.13
43.51
P/B 3.80
MDT's P/B is ranked higher than
72% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 4.16 vs. MDT: 3.80 )
MDT' s 10-Year P/B Range
Min: 2.03   Max: 6.83
Current: 3.8

2.03
6.83
P/S 4.40
MDT's P/S is ranked higher than
68% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 3.75 vs. MDT: 4.40 )
MDT' s 10-Year P/S Range
Min: 1.92   Max: 6.89
Current: 4.4

1.92
6.89
PFCF 19.90
MDT's PFCF is ranked higher than
93% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDT: 19.90 )
MDT' s 10-Year PFCF Range
Min: 9.2   Max: 70.14
Current: 19.9

9.2
70.14
POCF 18.10
MDT's POCF is ranked higher than
86% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 74.13 vs. MDT: 18.10 )
MDT' s 10-Year POCF Range
Min: 8.13   Max: 32.39
Current: 18.1

8.13
32.39
EV-to-EBIT 17.79
MDT's EV-to-EBIT is ranked higher than
85% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 68.02 vs. MDT: 17.79 )
MDT' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 23.8
Current: 17.79

8.8
23.8
PEG 3.09
MDT's PEG is ranked higher than
93% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDT: 3.09 )
MDT' s 10-Year PEG Range
Min: 1.06   Max: 11.65
Current: 3.09

1.06
11.65
Shiller P/E 24.80
MDT's Shiller P/E is ranked higher than
94% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDT: 24.80 )
MDT' s 10-Year Shiller P/E Range
Min: 12.18   Max: 49.65
Current: 24.8

12.18
49.65
Current Ratio 6.80
MDT's Current Ratio is ranked higher than
75% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. MDT: 6.80 )
MDT' s 10-Year Current Ratio Range
Min: 0.88   Max: 6.8
Current: 6.8

0.88
6.8
Quick Ratio 6.46
MDT's Quick Ratio is ranked higher than
79% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. MDT: 6.46 )
MDT' s 10-Year Quick Ratio Range
Min: 0.66   Max: 6.46
Current: 6.46

0.66
6.46
Days Inventory 145.98
MDT's Days Inventory is ranked higher than
72% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 157.38 vs. MDT: 145.98 )
MDT' s 10-Year Days Inventory Range
Min: 132.14   Max: 232.97
Current: 145.98

132.14
232.97
Days Sales Outstanding 74.32
MDT's Days Sales Outstanding is ranked higher than
74% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 78.80 vs. MDT: 74.32 )
MDT' s 10-Year Days Sales Outstanding Range
Min: 64.09   Max: 89.96
Current: 74.32

64.09
89.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.50
MDT's Dividend Yield is ranked higher than
56% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. MDT: 1.50 )
MDT' s 10-Year Dividend Yield Range
Min: 0.57   Max: 2.93
Current: 1.5

0.57
2.93
Dividend Payout 0.38
MDT's Dividend Payout is ranked higher than
86% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDT: 0.38 )
MDT' s 10-Year Dividend Payout Range
Min: 0.13   Max: 2.04
Current: 0.38

0.13
2.04
Dividend growth (3y) 7.60
MDT's Dividend growth (3y) is ranked higher than
78% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. MDT: 7.60 )
MDT' s 10-Year Dividend growth (3y) Range
Min: 7.6   Max: 28.4
Current: 7.6

7.6
28.4
Yield on cost (5-Year) 2.23
MDT's Yield on cost (5-Year) is ranked higher than
64% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 1.54 vs. MDT: 2.23 )
MDT' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 4.37
Current: 2.23

0.85
4.37
Share Buyback Rate 2.10
MDT's Share Buyback Rate is ranked higher than
94% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -1.40 vs. MDT: 2.10 )
MDT' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -8.5
Current: 2.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.57
MDT's Price/Tangible Book is ranked higher than
62% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 6.96 vs. MDT: 10.57 )
MDT' s 10-Year Price/Tangible Book Range
Min: 7.74   Max: 44.29
Current: 10.57

7.74
44.29
Price/DCF (Projected) 1.30
MDT's Price/DCF (Projected) is ranked higher than
94% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDT: 1.30 )
MDT' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 6.95
Current: 1.3

0.77
6.95
Price/Median PS Value 1.26
MDT's Price/Median PS Value is ranked higher than
72% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. MDT: 1.26 )
MDT' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 3.55
Current: 1.26

0.65
3.55
Price/Graham Number 3.42
MDT's Price/Graham Number is ranked higher than
82% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDT: 3.42 )
MDT' s 10-Year Price/Graham Number Range
Min: 2.1   Max: 11.15
Current: 3.42

2.1
11.15
Earnings Yield (Greenblatt) 5.60
MDT's Earnings Yield (Greenblatt) is ranked higher than
84% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. MDT: 5.60 )
MDT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 11.3
Current: 5.6

4.2
11.3
Forward Rate of Return (Yacktman) 7.11
MDT's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 5.08 vs. MDT: 7.11 )
MDT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.1   Max: 23.8
Current: 7.11

7.1
23.8

Analyst Estimate

Apr15 Apr16 Apr17 Apr18
Revenue(Mil) 24,822 28,996 30,027 30,946
EPS($) 4.02 4.23 4.43 5.43
EPS without NRI($) 4.02 4.23 4.43 5.43

Business Description

Industry: Medical Devices » Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW » details
Traded in other countries:2M6.Germany, MDT N.Mexico, MDT.Switzerland,
Medtronic Inc was founded in 1949, incorporated as a Minnesota corporation in 1957. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. The Company develops, manufactures, and markets its medical devices in more than 140 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. The Company functions in three operating segments that manufacture and sell device-based medical therapies: Cardiac and Vascular Group; Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group includes Cardiac Rhythm Disease Management that develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business; Coronary which includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories; The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. Its products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products; The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Its products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The Restorative Therapies Group includes Spine business which develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. Its Spine business also provides biologic solutions for the orthopedic and dental markets. Its Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity, and uro
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Freedom Fund Update – March 2015 Mar 02 2015 
Medtronic (MDT) Momentum at All-Time-High Levels, Knowles (KN) Rating Boosted Feb 21 2015 
Medtronic Q3 Earnings 2015 Exceeds Market Expectations Feb 19 2015 
A Robust Q4 Earnings Report From Boston Scientific Feb 10 2015 
A Look at John Hussman's Recent Additions to His Portfolio Feb 06 2015 
Steven Romick Shorts Alibaba, Medtronic in Q4 Jan 20 2015 
Toro: A Quality Company with Strong Prospects Dec 19 2014 
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 
Boston Scientific Lost the First Place in Innovation Dec 11 2014 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 

More From Our Partners
3 Best Performing Stocks in February - Analyst Blog Mar 2 2015 - ZACKS

More From Other Websites
Elliott Management exits position in Covidien Mar 04 2015
Stocks' Best Friend: Corporate Bond Market Mar 04 2015
Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare Conference Mar 03 2015
Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare Conference Mar 03 2015
NuVasive: Court Overturns Medtronic Award Mar 03 2015
Flex Pharma touts backing of Medtronic for product to treat cramps, muscle spasms Mar 03 2015
U.S. court orders new trial for damages in Medtronic patent case Mar 02 2015
Medtronic EVP & President Michael J. Coyle to Speak at Cowen Healthcare Conference Feb 27 2015
Medtronic EVP & President Michael J. Coyle to Speak at Cowen Healthcare Conference Feb 27 2015
Medtronic Announces Irish High Court Approval of Share Premium Reduction Feb 27 2015
Medtronic Announces Irish High Court Approval of Share Premium Reduction Feb 27 2015
MEDTRONIC INC Files SEC form 10-Q, Quarterly Report Feb 27 2015
Medtronic's VenaSeal Wins FDA Nod for Vericose Veins Cure - Analyst Blog Feb 26 2015
Tesla Motors (TSLA), Wal-Mart Stores (WMT), Medtronic PLC (MDT): Billionaire Jim Simons’ RenTech... Feb 26 2015
Cyberonics Soars On Earnings Beat, Tax Inversion Deal Feb 26 2015
Medtronic Adds Advanced Uro-Solutions to Neuromodulation - Analyst Blog Feb 24 2015
Street Talk: CSC, STJ, AEO, RIG & PETX Feb 24 2015
FDA Approves the VenaSeal(TM) Closure System for Treatment of Clinically Symptomatic Venous Reflux Feb 24 2015
FDA Approves the VenaSeal(TM) Closure System for Treatment of Clinically Symptomatic Venous Reflux Feb 24 2015
Medtronic's Artificial Pancreas Technology: Key to Diabetes Cure? - Analyst Blog Feb 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK